[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-404851-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-404851-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","prep-2018-new-potential-population-wide-benefits","PrEP - 2018 - New potential population-wide benefits","","2018 PrEP overview explaining pre-exposure prophylaxis as an antiretroviral-medication strategy used before exposure to reduce the risk of HIV infection for people at high risk. It summarizes evidence from studies since 2012 showing large reductions in new infections, notes key regulatory milestones including FDA approval in 2012 and CDC guidelines in 2014, and highlights WHO guidance enabling broader adoption. It also discusses an insurance underwriting perspective, including safety findings and discrimination concerns, and lists supporting bibliography items.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/prep-2018-new-potential-population-wide-benefits/404851/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/prep-2018-new-potential-population-wide-benefits/404851.png","ImageObject",300,407,{"name":42,"@type":43},"SundayMiles","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-27",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is PrEP and how does it work?","Question",{"text":63,"@type":64},"PrEP uses antiretroviral medication before exposure, taken daily or intermittently, to reduce the risk of HIV infection when a person is exposed to the virus.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What evidence supports PrEP’s effectiveness and safety?",{"text":68,"@type":64},"Since the first studies in 2012, PrEP has shown a significant reduction in new infections among exposed people. The document states PrEP is safe and highly effective, reducing the risk from unprotected sex by over 90%.",{"name":70,"@type":61,"acceptedAnswer":71},"What regulatory and guideline milestones are mentioned for PrEP?",{"text":72,"@type":64},"The document notes FDA approval of oral PrEP in 2012, CDC guidelines in 2014, and WHO guidelines in 2015 recommending PrEP for people at substantial risk. It also mentions that many countries implemented PrEP policies and that 24 countries approved PrEP guidelines for use in 2018.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},404851,1790672423,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":26,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":97,"preview_page_count":4},1099529839202,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","PrEP  \n2018  \nNew potential population-wide benefits  \nSince the introduction of tritherapies, the survivalof patients infected with HIV has improved considerably. This has only been possible thanks to access to medical care and drugs.  \nToday, a new prevention approach offers a treatment against human immunodeficiency virus (HIV) infection: the Pre-Exposure Prophylaxis (PrEP).  \nAuthor  \nGabriela Buffet, Medical Officer Underwriting and Claims R&D Centre  \nPre-exposure Prophylaxis Against HIV Infection  \nPrEP consists of the use of antiretroviral medication before exposure (daily or intermittently) to reduce the risk of becoming infected if the uninfected person is exposed to the virus. It is prescribed to men and women that are exposed toa high risk of contracting HIV.  \nSince the first studies in 2012, PrEP has showed a significant reduction in the number of new infections between exposed people. In fact, PrEP is safe and highly effective, and it can reduce the risk of HIV infection from unprotected sex by over 90% . Several studies have shown that users who take the drug daily are at nearly zero risk of HIV infection.  \nThe US Food and Drug Administration (FDA) became the first national body to approve oral PrEP in 2012, which was subsequently followed by Centre for Disease Control (CDC) guidelines in 2014.  \nIn 2015, the World Health Organization (WHO) recognised the potential population-wide benefits of PrEP and released new guidelines recommending PrEP be offered to all people who are at substantial risk of HIV. Since then, PrEP policies have been implemented in most countries. In 2018, 24 countries approved PrEP guidelines for use.  \nILLUSTRATION OF THE LAST 20 YEARS OFARV-BASED PREVENTION PRODUCT DEVELOPMENT  \nEvents above the timeline are related to theARV-based prevention product pipeline and those below the line denote important milestones related to HIV prevention and care over the past 20 years. Dates and products represent timing of results unless otherwise noted. Data for this timeline was extracted from several sources.  \nProduct pipeline  \n2002 2007 2012  \nFirst PMTCT recommendations  \nPEPFAR and ARV treatment in Africa  \nHPTN 052 – Test and treat proof of concept  \nUpdated USCDC PrEP Guidelines  \nPreliminary US CDC PrEP Guidelines (2011 & 2012)  \nWHO PrEP Guidelines  \nSouthern African Clinician’s Society PrEP Guidelines  \n1997 2017  \nMilestones  \nPost-exposure prophylaxis (1994) Carrageenan study  \nBufferGel  \nCellulose sulfate gel MDP 301/pro 2000 gel CAPRISA 004 geliPrEX study (MSM) TDF2 and Partners PrEP (couples)  \nFEMPrEP and VOICE Bangkok TDF (IDUs)  \nFACTS 001 Dapivirine ring studies  \nPrEP approved in 15 countires  \n2018  \nPaolo De Martin Editor  \nSCOR  \n5, avenue Kleber  \n75795 Paris Cedex 16 France  \n[www.scor.com](www.scor.com)  \nREGULATORY STATUS OF TRUVADA FOR PrEP  \nUpdated October 2017; [https://www.hptn.org/resources/prevention](https://www.hptn.org/resources/prevention)  \nTruvada approved for  \nprevention1  \nAustralia Belgium Canada England France Greece Israel Kenya Lesotho* Malawi Namibia Netherlands  \nNew Zealand Peru Scottland South Africa Slovenia Swaziland* Taiwan  \nTanzania Thailand United States Zambia  \nZimbabwe  \nRegulatory application submitted for a prevention indication for Truvada2  \nBrazil Chile HongKong Nigeria South Korea Ukraine  \n*Approved via import license from South Africa  \n1. India, SA and Kenya have generic PrEP approval.  \n2. The European Commission granted Gilead marketing authorization for Truvada as PrEP in Q3 2016. This should encourage countries with in the EU to make PrEP available within their national health systems, based on cost factors and individual country regulatory requirements  \nINSURANCE PERSPECTIVE:  \nSome critics of the PrEP policy say that people taking PrEP could increase risky sexual behaviour, however no such risk has been reported in studies.  \nPrEP is an HIV prevention strategy where individuals who are not infected with HIV but may be at ri","cbCainvm2Sg0vWzU","https://ap.wps.com/l/cbCainvm2Sg0vWzU","pdf",941615,"English","# PrEP\n## New prevention approach and risk reduction\n## Evidence since 2012 and regulatory milestones\n## ARV-based prevention product development timeline\n## Regulatory status of Truvada for PrEP\n## Insurance perspective and considerations\n## Bibliography","[{\"question\":\"What is PrEP and how does it work?\",\"answer\":\"PrEP uses antiretroviral medication before exposure, taken daily or intermittently, to reduce the risk of HIV infection when a person is exposed to the virus.\"},{\"question\":\"What evidence supports PrEP’s effectiveness and safety?\",\"answer\":\"Since the first studies in 2012, PrEP has shown a significant reduction in new infections among exposed people. The document states PrEP is safe and highly effective, reducing the risk from unprotected sex by over 90%.\"},{\"question\":\"What regulatory and guideline milestones are mentioned for PrEP?\",\"answer\":\"The document notes FDA approval of oral PrEP in 2012, CDC guidelines in 2014, and WHO guidelines in 2015 recommending PrEP for people at substantial risk. It also mentions that many countries implemented PrEP policies and that 24 countries approved PrEP guidelines for use in 2018.\"}]","PrEP - 2018 - New potential population-wide benefits | PDF",1790551318]